S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:UTHR - United Therapeutics Stock Price, Forecast & News

$93.90
-0.92 (-0.97 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$89.89
Now: $93.90
$96.48
50-Day Range
$79.43
MA: $97.28
$115.35
52-Week Range
$74.31
Now: $93.90
$121.11
Volume583,300 shs
Average Volume613,887 shs
Market Capitalization$4.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.79
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
United Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 billion
Book Value$63.36 per share

Profitability

Net Income$-104,500,000.00

Miscellaneous

Employees860
Market Cap$4.12 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.


United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

How has United Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, UTHR shares have decreased by 0.1% and is now trading at $93.90. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of United Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for United Therapeutics.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for United Therapeutics.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, February, 26th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.47 by $1.27. The biotechnology company had revenue of $311.10 million for the quarter, compared to analyst estimates of $357.14 million. United Therapeutics had a negative return on equity of 4.03% and a negative net margin of 7.21%. The company's revenue was down 18.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.34 earnings per share. View United Therapeutics' earnings history.

What price target have analysts set for UTHR?

10 Wall Street analysts have issued 12-month price objectives for United Therapeutics' stock. Their forecasts range from $80.00 to $243.00. On average, they expect United Therapeutics' share price to reach $127.20 in the next year. This suggests a possible upside of 35.5% from the stock's current price. View analysts' price targets for United Therapeutics.

Has United Therapeutics been receiving favorable news coverage?

Press coverage about UTHR stock has trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutUnited Therapeutics.

Are investors shorting United Therapeutics?

United Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,165,100 shares, an increase of 37.6% from the February 27th total of 2,300,000 shares. Based on an average trading volume of 682,500 shares, the days-to-cover ratio is presently 4.6 days. Approximately 7.5% of the shares of the stock are short sold. View United Therapeutics' Current Options Chain.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), NVIDIA (NVDA), General Electric (GE), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), AT&T (T), Applied Materials (AMAT), Skyworks Solutions (SWKS) and Allergan (AGN).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $93.90.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $4.12 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. United Therapeutics employs 860 workers across the globe. View additional information about United Therapeutics.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com/.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  473 (Thanks for Voting!)
Underperform Votes:  633 (Thanks for Voting!)
Total Votes:  1,106
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel